Participating Faculty

The American Journal of

Managed Care

This supplement tocontainsinformation on improvingoutcomes in diabetes throughthe appropriate use of newtechnologies and innovativebenefit design strategies.

Faculty

Andrew J. Ahmann, MD, MS

Associate Professor of Medicine

Division of Endocrinology, Diabetes and Clinical Nutrition

Oregon Health and Science University

Director, Diabetes Care Center

Portland, Oregon

Jan Berger, MD, MJ

Senior Vice President

Chief Clinical Officer

Caremark Inc

North Brook, Illinois

Lawrence Blonde, MD, FACP, FACE

Director

Ochsner Diabetes Clinical Research Unit

Section on Endocrinology, Diabetes, and Metabolism

Associate Residency Program Director

Department of Internal Medicine

Ochsner Clinic Foundation

New Orleans, Louisiana

Curtis L.Triplitt, PharmD, CDE

Assistant Professor

Department of Medicine

Division of Diabetes

Clinical Assistant Professor of Pharmacy

Clinical Pharmacy Program

University of Texas Health Science Center

San Antonio, Texas

Faculty Disclosures

These participants report relationships with the following pharmaceuticalcompanies:

Andrew J. Ahmann, MD, MS

Consultant:

• The Amylin-Lilly Alliance
• Ortho-Clinical Diagnostic
• sanofi-aventis

Speaker's Bureau:

• The Amylin-Lilly Alliance
• Novo Nordisk
• sanofi-aventis

Jan Berger, MD, MJ

Stockholder/Employee:

• Caremark

Lawrence Blonde, MD, FACP, FACE

Research Funding:

• Amylin
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly
• MannKind Corporation
• Merck
• Novartis
• Novo Nordisk
• Pfizer
• sanofi-aventis

Consultant and Speaker:

• Abbott
• Amylin
• Eli Lilly
• GlaxoSmithKline
• Lifescan
• Merck/Schering-Plough
• Novartis
• Pfizer
• sanofi-aventis

Speaker:

• Takeda
• Wyeth

Consultant:

• AstraZeneca

Curtis L.Triplitt, PharmD, CDE

Speaker:

• Novartis Pharmaceuticals
• Pfizer Inc
• sanofi-aventis

Advisory Board:

• Amylin

The American Journal of

Managed Care

Signed disclosures are on file at the office of , Princeton, New Jersey.

The American

Journal of Managed Care

It is the policy of to haveall faculty who participate inprograms sponsored bypharmaceutical companiesdisclose any real or apparentconflicts of interest.

It is the policy of BCMEto require the disclosure ofany financial relationships orother relationships that afaculty member has with themanufacturers of any commercialproducts or providers relevantto the topics or therapeutic areasbeing discussed.

STAFF DISCLOSURES

BCME staff members andreviewers involved in clinicalcontent development have norelevant financial relationshipsto disclose.

BCME has received educationalgrants from The Amylin-LillyAlliance for CE/CME activities.

This CME activity was planned and produced in accordance with the Accreditation Council for Continuing MedicalEducation Essential Areas and Policies.

ACTIVITY OVERVIEW

This activity will update participants on the state of diabetes in the United States, including epidemiology, consensusguidelines, and performance measures designed to evaluate and improve management of this population. This activitywill ensure that managed care professionals are informed about new and investigational pharmacotherapeutic agents andtechnologies in the diabetes armamentarium. New benefit design strategies and their potential application to this diseasestate will be discussed, explored, and debated.

TARGET AUDIENCE

This activity is for managed healthcare professionals, especially pharmacy directors and medical directors, with an interestin improving members'outcomes in diabetes through the appropriate use of new technologies and innovative benefitdesign strategies.

EDUCATIONAL OBJECTIVES

After completing this educational supplement, the participant should be able to:

• Describe some of the current gaps in the management of diabetes in the US healthcare system.
• Recognize current standards of care for the management of diabetes and available quality improvementinitiatives to help optimize health outcomes.
• Evaluate new and emerging diabetes technologies and classes of medications to determine theirappropriate place in therapy.
• Analyze the potential impact of novel pharmacy benefit designs in diabetes management.

ACCREDITATION AND CREDIT DESIGNATION

The Bimark Center for Medical Education (BCME) is accredited by the Accreditation Council for PharmacyEducation (ACPE) as a provider of continuing pharmacy education (No. 799).

This program is acceptable for 2.0 hours (0.2 CEU) of continuing education credit in states that recognize ACPE-accreditedproviders. The ACPE Universal Program Number for this program is 799-000-07-002-H01.

The BCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical education for physicians.

AMA PRA Category 1 Credits

BCME designates this educational activity for a maximum of 2 ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT

This activity is supported by an educational grant from Amylin Pharmaceuticals and Eli Lilly and Company.

Initial Release Date: April 1, 2007

Expiration Date: April 1, 2008

DISCLOSURE OF UNLABELED/UNAPPROVED USES OF DRUGS OR DEVICES

Participants are advised that some of the discussions in this continuing medical education activity may contain referencesto unlabeled or unapproved uses of drugs or devices, and are indicated as such throughout the activity.

•••

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Download PDF: Participating Faculty